Category: Novacyt Group

SNPsig® VariPLEX™ is able to detect six key mutations of SARS-CoV-2 using PCR genotyping in under two hours Paris, France and Camberley, UK – 24 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2 February 2021, the Company will  launch SNPsig®

Paris, France and Camberley, UK – 17 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ service with the launch of mobile processing laboratories (MPL) to provide rapid turnaround polymerase chain reaction (PCR) testing on-site. Testing will be performed using mid-nose nasal swabs,

Paris, France and Camberley, UK – 15 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 15 March 2021 that, as at 12 March 2021, BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.81% (1,986,434 shares). http://novacyt.com/wp-content/uploads/2021/03/Novacyt-BlackRock-holdings-15.03.2021-ENGLISH-No.-2.pdf